新型病毒引发罕见肝癌

2015-09-01 佚名 临床肝胆病杂志

有时候病毒不只是会引发简单的感染,其往往还会参与严重疾病的发病,比如肝癌,乙肝和丙肝病毒通常都会引发患者感染的发生;近日一项刊登于国际杂志Nature Genetics的研究论文中,来自法国巴黎第七大学的研究人员通过研究首次鉴别出了一种引发罕见肝癌的新型病毒。每年都有超过8000名个体被诊断为肝癌,而肝癌主要影响男性,也是引发患者死亡的主要原因;在不同类型的肝癌中,肝细胞癌通常是由肝脏中的疾病损伤

有时候病毒不只是会引发简单的感染,其往往还会参与严重疾病的发病,比如肝癌,乙肝和丙肝病毒通常都会引发患者感染的发生;近日一项刊登于国际杂志Nature Genetics的研究论文中,来自法国巴黎第七大学的研究人员通过研究首次鉴别出了一种引发罕见肝癌的新型病毒。

每年都有超过8000名个体被诊断为肝癌,而肝癌主要影响男性,也是引发患者死亡的主要原因;在不同类型的肝癌中,肝细胞癌通常是由肝脏中的疾病损伤所引发,而肝脏的损伤很有可能是因为个体过度饮酒、肥胖或者慢性乙肝/丙肝病毒感染,从而引发肝脏损伤直至肝硬化发生。

肝硬化患者会进行定期检查来诊断是否患肝癌,然而在5%的病例中,肝癌往往发生于非肝硬化的患者中,然而研究者并不清楚具体的原因。研究者Jessica Zucman-Rossi表示,文章中我们重点就对这一类患者进行研究来确定引发其患肝癌的风险因素。

通过对11名患者机体肿瘤细胞的基因组进行研究,研究者发现了来自2型腺病毒伴随病毒(adeno-associated virus type 2, AAV-2)的DNA片段会插入到肿瘤细胞的基因组中,截止到现在为止AAV2一直被认为是对人类无致病性的病毒,为了证实该病毒参与了肝癌的发生,科学家们将正常组织同肿瘤组织进行对比,随后证实了他们的假设,即在11位患者中,2型腺病毒的DNA通常会整合入肿瘤细胞中,而且其中8名患者并未患肝硬化,这8名患者中有6名个体都没有患肝癌的风险因子。

通过对肝癌细胞进行详细的研究,研究者发现,当AAV2将其DNA插入到病人肿瘤细胞的基因组中时,病毒就会靶向作用对细胞增殖关键的基因;而且研究者还表示,AAV2会导致这些基因出现过表达的情况,从而促进肿瘤发展。

最后研究者指出,本文研究中我们发现,此前被认为无害的2型腺病毒或许会参与肝癌的发生,AAV2通常被用作基因疗法的载体,尽管其DNA可以整合入肿瘤细胞的基因组中促进特殊基因表达的现象非茶罕见,但我们需要高度警惕该病毒的使用是否会影响疗法的应用以及给患者带来的额外风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=42959, encodeId=3d6a4295915, content=外国的科研就是比我们强, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3321662285, createdName=1ddf0460m69(暂无匿称), createdTime=Tue Nov 10 21:48:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36374, encodeId=264b363e418, content=拓宽了对肝癌致病因素的认识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 00:24:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36370, encodeId=604c363e0bb, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Fri Sep 04 00:04:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36354, encodeId=b977363544c, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:22:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467100, encodeId=2b5d146e100ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Sep 03 01:45:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-11-10 1ddf0460m69(暂无匿称)

    外国的科研就是比我们强

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=42959, encodeId=3d6a4295915, content=外国的科研就是比我们强, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3321662285, createdName=1ddf0460m69(暂无匿称), createdTime=Tue Nov 10 21:48:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36374, encodeId=264b363e418, content=拓宽了对肝癌致病因素的认识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 00:24:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36370, encodeId=604c363e0bb, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Fri Sep 04 00:04:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36354, encodeId=b977363544c, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:22:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467100, encodeId=2b5d146e100ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Sep 03 01:45:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-04 fengzhigu

    拓宽了对肝癌致病因素的认识!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=42959, encodeId=3d6a4295915, content=外国的科研就是比我们强, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3321662285, createdName=1ddf0460m69(暂无匿称), createdTime=Tue Nov 10 21:48:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36374, encodeId=264b363e418, content=拓宽了对肝癌致病因素的认识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 00:24:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36370, encodeId=604c363e0bb, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Fri Sep 04 00:04:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36354, encodeId=b977363544c, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:22:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467100, encodeId=2b5d146e100ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Sep 03 01:45:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-04 lecoo

    拜读

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=42959, encodeId=3d6a4295915, content=外国的科研就是比我们强, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3321662285, createdName=1ddf0460m69(暂无匿称), createdTime=Tue Nov 10 21:48:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36374, encodeId=264b363e418, content=拓宽了对肝癌致病因素的认识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 00:24:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36370, encodeId=604c363e0bb, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Fri Sep 04 00:04:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36354, encodeId=b977363544c, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:22:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467100, encodeId=2b5d146e100ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Sep 03 01:45:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 byzh1990

    需要进一步研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=42959, encodeId=3d6a4295915, content=外国的科研就是比我们强, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3321662285, createdName=1ddf0460m69(暂无匿称), createdTime=Tue Nov 10 21:48:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36374, encodeId=264b363e418, content=拓宽了对肝癌致病因素的认识!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 00:24:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36370, encodeId=604c363e0bb, content=拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Fri Sep 04 00:04:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36354, encodeId=b977363544c, content=需要进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:22:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467100, encodeId=2b5d146e100ee, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Sep 03 01:45:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 syscxl

相关资讯

腺病毒载体疫苗研究获进展

  最近,中科院广州生物医药与健康研究院特聘研究员陈凌博士带领其研究组成员孙彩军博士、冯立强博士等研发了一种可克服体内腺病毒中和抗体的新技术AVIP,并在恒河猴模型中利用腺病毒载体艾滋病疫苗进行了概念验证。相关成果发表于国际病毒学权威期刊《病毒学期刊》(J Virol. 2012,86(20):11031-42.)。   腺病毒(Adenovirus),尤其是人5型腺病毒(Ad5)已被广泛作为重

Cell Host & Micro:腺病毒逃脱干扰素介导的天然免疫反应的机制

近日,来自劳森健康研究所和西方大学的研究者发现腺病毒在机体免疫反应中扮演着重要作用,相关研究成果刊登在了国际著名杂志Cell Host & Microbe上。腺病毒感染常常引发轻微的呼吸系统疾病,最终引发咳嗽和喉痛等症状。然而当1960年研究者发现腺病毒还可以引发啮齿类动物患瘤,从此研究者才对腺病毒进行了深入研究。肿瘤的产生是因为腺病毒使得细胞分裂不受控制,而且腺病毒可以逃脱免疫系统的监视

JID:腺病毒、札幌病毒以及星状病毒与儿童急性胃肠炎相关

     5种肠道病毒在年龄小于5岁的急性胃肠炎患者和健康者中的年龄分布 急性胃肠炎是儿科常见的疾病和常见的死亡病因。全球每年大约有90万初生儿和儿童死于腹泻。虽然因腹泻而死亡在发达国家里并不常见,但涉及大量的医疗健康费用,从而对社会经济产生巨大的负面影响。最近的数据显示,美国每年1.79亿例胃肠道疾病中,有1.418亿例(约80%)由非特异性病原体或不明病原体引起。 病毒是引起年龄小于5岁

Science TM:表达Ag85A的复制缺陷的腺病毒载体5疫苗可能具有强大抗结核病作用

加拿大麦克马斯特大学研究人员最近研发出一种结核病疫苗,这一成果有望取代目前唯一且已使用了50年的结核病疫苗——卡介菌苗(BCG),研究结果在日前出版的《科学—转化医学》杂志上发表,论文显示新疫苗十分安全且对结核病有强大免疫效果。这种疫苗由表达Ag85A的复制缺陷的腺病毒载体5疫苗AdHu5Ag85A ,具有强大刺激T细胞免疫的机能。 结核病是全世界仅次于艾滋病的第二大致命传染病。据统计,世界上三

Cell Stem Cell:亨廷顿疾病新的治疗策略

亨廷顿疾病是一种神经退化疾病,这类疾病的部分特征是纹状体多棘投射神经元减少(MSNs)。Benraiss研究团队在这一疾病的治疗领域获得了突破。他们通过脑室内注射带有BDNF和noggin的腺病毒,发现引发了新纹状体中新神经元的产生。单次脑室内注射AAV4-BDNF和AAV4-noggin腺病毒能引发长期募集新的MSNs,而这种反应不管在野生型小鼠还是亨廷顿动物模型R6/2中都是一致的。直接BD